Ram Mukunda
Known title: CEOCIK: 0001047575
Associated companies
Transaction History
| IGC | ▼ Sell | Gift | 100,000 | $0 | 9/25/2026 | View on chart |
| IGC | ▼ Sell | Gift | 100,000 | $0 | 9/25/2026 | View on chart |
| IGC | ▲ Buy | Grant | 2,226,475 | $601K | 6/30/2026 | View on chart |
| IGC | ▲ Buy | Option Exercise | 16,667 | $0 | 4/1/2026 | View on chart |
| IGC | ▲ Buy | Option Exercise | 33,332 | $0 | 4/1/2026 | View on chart |
| IGC | ▲ Buy | Option Exercise | 333,333 | $0 | 4/1/2026 | View on chart |
| IGC | ▲ Buy | Option Exercise | 323,077 | $84K | 4/1/2026 | View on chart |
| IGC | ▲ Buy | Option Exercise | 50,000 | $0 | 2/3/2026 | View on chart |
| IGC | ▼ Sell | Gift | 100,000 | $0 | 10/17/2025 | View on chart |
| IGC | ▲ Buy | Option Exercise | 333,333 | $0 | 3/13/2024 | View on chart |
| IGC | ▲ Buy | Option Exercise | 233,334 | $0 | 3/13/2024 | View on chart |
| IGC | ▲ Buy | Option Exercise | 333,334 | $0 | 3/13/2024 | View on chart |
| IGC | ▲ Buy | Option Exercise | 251,250 | $0 | 3/13/2024 | View on chart |
| IGC | ▼ Sell | Gift | 200,000 | $0 | 3/13/2024 | View on chart |
| IGC | ▲ Buy | Option Exercise | 16,667 | $0 | 3/13/2024 | View on chart |
| IGC | ▲ Buy | Option Exercise | 16,667 | $0 | 3/13/2024 | View on chart |
| IGC | ▼ Sell | Gift | 400,000 | $0 | 6/23/2023 | View on chart |
| IGC | ▲ Buy | Option Exercise | 333,333 | $0 | 3/31/2023 | View on chart |
| IGC | ▲ Buy | Option Exercise | 233,334 | $0 | 3/31/2023 | View on chart |
| IGC | ▲ Buy | Option Exercise | 16,667 | $0 | 3/31/2023 | View on chart |
| IGC | ▲ Buy | Option Exercise | 16,667 | $0 | 3/31/2023 | View on chart |
| IGC | ▲ Buy | Option Exercise | 200,000 | $0 | 6/1/2022 | View on chart |
| IGC | ▲ Buy | Option Exercise | 600,000 | $0 | 5/31/2022 | View on chart |
| IGC | ▲ Buy | Option Exercise | 333,334 | $0 | 3/21/2022 | View on chart |
| IGC | ▲ Buy | Option Exercise | 16,667 | $0 | 3/21/2022 | View on chart |
| IGC | ▲ Buy | Grant | 0 | $0 | 12/20/2021 | View on chart |
| IGC | ▲ Buy | Grant | 0 | $0 | 12/20/2021 | View on chart |
| IGC | ▲ Buy | Grant | 1,000,000 | $0 | 5/13/2021 | View on chart |
| IGC | ▲ Buy | Grant | 50,000 | $0 | 5/13/2021 | View on chart |
| IGC | ▼ Sell | Open Market | 50,000 | $107K | 3/2/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
IGC Pharma Enters Phase 2 Alzheimer's Trial; DEA Hearing Paused
IGC Pharma has joined a Phase 2 study for its CALMA drug in Alzheimer’s disease, with results due in Q4 2026. Separately, a U.S. DEA judge paused a hearing on marijuana rescheduling after opponents cited a government report that highlighted gaps in federal procedures. The pause may affect the regulatory environment for cannabis‑derived products, while the trial marks a new development for IGC’s pipeline.
IGC Pharma Enters Phase 2 Alzheimer's Trial; DEA Hearing Paused. IGC Pharma has joined a Phase 2 study for its CALMA drug in Alzheimer’s disease, with results due in Q4 2026. Separately, a U.S. DEA judge paused a hearing on marijuana rescheduling after opponents cited a government report that highlighted gaps in federal procedures. The pause may affect the regulatory environment for cannabis‑derived products, while the trial marks a new development for IGC’s pipeline.